Novozymes A/S
USPTO PatentsView assignee record - 770 granted patents across 73 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).
The verdict
According to USPTO PatentsView, Novozymes ranks #581 of 49,997 tracked US assignees by granted-patent volume, with 770 patents across 73 technology areas.
- #581
- of 49,997 US assignees by volume
- Top 2%
- by Innovation Score (63.6/100)
- 18.7
- avg claims per patent
- -7%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R581 · Foreign Corporation #581 · 770 grants
GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL
- GRANTS-MID 770 grants
- TOP-DECILE #581/49,997
- PHOTO-FINISH Axis AB
- CPC-WIDE C12N · 73 areas
- INNOV-STRONG 63.6/100
- CLAIMS-RICH 18.7 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-FLAT -7% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Axis AB (±1 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Novozymes’s 63.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Novozymes
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Maxell · near
Maxell · near
64 score
- Hefei Institutes of… · near
Hefei Institutes of… · near
64 score
- MKS Instruments · near
MKS Instruments · near
64 score
- Novozymes A/S · this assignee
Novozymes A/S · this assignee
64 score
- Rolls-Royce · near
Rolls-Royce · near
64 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Novozymes's Innovation Score is 63.6/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Novozymes?
Each dot is one of Novozymes’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novozymes’s own 18.7 claims/patent is ABOVE the 17.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
How Novozymes's grant cadence moved
Between 2020–2024, Novozymes A/S received 350 grants versus 378 in 2015–2019 (-7% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2020 at 98 grants and bottomed in 2015 at 48. Lead class C12N accounts for 85.2% of the portfolio across 73 subclasses. Volume neighbours: Mitsubishi Electric Research Laboratories, Inc. (#577) and Medtronic Minimed, Inc. (#585).
Novozymes's three-year grant acceleration
From 2019–2021 to 2022–2024, Novozymes A/S moved from 263 to 173 grants (0.66x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,282. See the growth leaderboard.
Who files at Novozymes's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Mitsubishi Electr…
Mitsubishi Electric Research Laboratories, Inc.
780 patents
- Chevron Phillips…
Chevron Phillips Chemical Company LP
777 patents
- SK Telecom
SK Telecom Co., Ltd.
772 patents
- Hitachi Construct…
Hitachi Construction Machinery Co., Ltd.
771 patents
- Novozymes A/S ◀
Novozymes A/S
770 patents
- Axis AB
Axis AB
769 patents
- Globalfoundries S…
GlobalFoundries Singapore Pte. Ltd.
769 patents
- Janssen Pharmaceu…
Janssen Pharmaceuticals, Inc.
769 patents
- Medtronic Minimed
Medtronic Minimed, Inc.
769 patents
What this shows Novozymes holds 770 patents at rank #581, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Novozymes
By rank, the assignees closest to #581 in granted patent volume.
- Mitsubishi Electric Research Laboratories, Inc. #577 · 780 patents
- Chevron Phillips Chemical Company LP #578 · 777 patents
- SK Telecom Co., Ltd. #579 · 772 patents
- Hitachi Construction Machinery Co., Ltd. #580 · 771 patents
- Axis AB #582 · 769 patents
- GlobalFoundries Singapore Pte. Ltd. #583 · 769 patents
- Janssen Pharmaceuticals, Inc. #584 · 769 patents
- Medtronic Minimed, Inc. #585 · 769 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Novozymes's primary technology class.
- Monsanto Technology LLC 1,335 in class
- The Regents of the University of California 1,161 in class
- Immatics Biotechnologies GmbH 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President and Fellows of Harvard College 594 in class
- Massachusetts Institute of Technology 541 in class
- The Trustees of the University of Pennsylvania 537 in class
- Regeneron Pharmaceuticals, Inc. 458 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Novozymes, neither rank-band nor same-CPC leaders (those blocks stay above). In C12N (Microorganisms OR Enzymes), Novozymes ranks #3 of 4,144 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (64 here).
Similar claim depth
Nearest assignees by average claims per patent (18.7 here).
Novozymes's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
64 Top 2% higher than 98% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 48 | 6.2% |
| 2016 | 79 | 10.3% |
| 2017 | 85 | 11.0% |
| 2018 | 80 | 10.4% |
| 2019 | 86 | 11.2% |
| 2020 | 98 | 12.7% |
| 2021 | 79 | 10.3% |
| 2022 | 66 | 8.6% |
| 2023 | 49 | 6.4% |
| 2024 | 58 | 7.5% |
| 2025partial year | 42 | 5.5% |
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Novozymes A/S's patent record in context - here's where to go next.
- Novozymes A/S's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 85.2% of its portfolio - see every assignee active in that class. Explore C12N
- Ranked #581 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Novozymes A/S against Mitsubishi Electric Research Laboratories, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 63.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.